People: Transgene SA (TRNG.PA)
28 Feb 2020
Ms. Maud Brandely has been Member of the Management Committee as well as Vice President - Clinical Development, Clinical Operations and Regulatory Affairs at Transgene SA since 2016. She was the Director of Clinical Oncology Development at Pierre Fabre until February 2016. She was responsible for all phase 1 to phase 3 clinical trials. She played a role in the registration of oral Navelbine products for the treatment of both breast and lung cancer and for vinflunine in bladder cancer. Prior to Pierre Fabre, she was Director of Taxotere Clinical Development at Rhône Poulenc (RPR, now Sanofi), where she was responsible for setting up clinical studies with the aim of registration in the United States and Europe. As such, she divided her time between Collegeville and Paris to oversee her US and European teams. Prior to RPR, she worked for Hoechst-Roussel-Uclaf (now Sanofi) and was involved in the development of cytokines (IL-2, IFN) and cytotoxics. She is an MD and has a PhD in immunology.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|